Effects of Pulmonary Rehabilitation on Walking Speed in Patients With COPD or ILD Patients
NCT ID: NCT04159129
Last Updated: 2019-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
43 participants
OBSERVATIONAL
2019-11-07
2020-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Coping Strategies Within Pulmonary Rehabilitation in Patients With IPF and COPD
NCT04257630
Effects of Treadmill Versus Cycling Endurance Training in Patients With COPD
NCT03120169
Effects of Non-invasive Ventilation on Rehabilitation Outcome in COPD-patients
NCT01384981
Effects of Nocturnal Non-invasive Ventilation on Energy Expenditure in Patients With Severe Chronic Obstructive Pulmonary Disease
NCT01961245
Continuous Versus Interval Walking Training in Patients With COPD - a Pilot Study
NCT02209207
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
An UK study (Nolan et al., Thorax 2018) showed that only 10.7% of the 926 patients with moderate COPD attained a walking speed of 1.2m/sec. As PR plays a key role in the management of chronic lung diseases in order to improve patients´ exercise capacity, the aim of this study was to evaluate the PR effects on the Walking Speed in patients with COPD or ILD. The investigators hypothesize that PR improves the ability to cross the road in the appropriate time.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Indication: COPD or ILD
* COPD; FEV1 \<50%
* ILD: FVC \<70%
* written informed consent
Exclusion Criteria
40 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Psychologische Hochschule Berlin
UNKNOWN
Schön Klinik Berchtesgadener Land
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Klaus Kenn
Prof. Dr. Klaus Kenn
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Klaus Kenn, Prof.
Role: PRINCIPAL_INVESTIGATOR
Schön Klinik Berchtesgadener Land
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Schön Klinikum Berchtesgadener Land
Schönau am Königssee, Bavaria, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Ampel2019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.